Literature DB >> 2477947

Immunocytochemical reactivity of breast cancer tissue with antibodies to neuron-specific enolase and an adenocarcinoma-associated glycolipid antigen.

H Ingelman-Sundberg1, B Wikström, N Stormy, P Sundelin, A Hjerpe.   

Abstract

The immunocytochemical reactivity of breast cancers to antibodies raised against neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and an adenocarcinoma-associated glycolipid antigen (IR-14) was studied in relation to the long-term outcome of the neoplastic disease. The patients whose tumours exhibited reactivity with the IR-14 and anti-NSE antibodies had a considerably better 5-year and long-term survival than those without such reactivity. Assessment of DNA-ploidy of the tumour cells was also relevant for long-term prognosis, immunohistochemistry giving additional prognostic information among aneuploid tumours. Reactivity with polyclonal CEA antibodies was of no prognostic value. It is suggested that tumours carrying the IR-14 reactive epitope, which was originally isolated from circulating antigen-antibody complexes, might evoke a favourable immune response and thus improve the survival of the patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477947     DOI: 10.1007/bf00718647

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  15 in total

1.  A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue.

Authors:  E Heyderman; K Steele; M G Ormerod
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

2.  The use of monoclonal antibodies for histopathologic diagnosis of human malignancy.

Authors:  K C Gatter; D Y Mason
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

3.  Use of monoclonal antibodies for the histopathological diagnosis of human malignancy.

Authors:  K C Gatter; Z Abdulaziz; P Beverley; J R Corvalan; C Ford; E B Lane; M Mota; J R Nash; K Pulford; H Stein; J Taylor-Papadimitriou; C Woodhouse; D Y Mason
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

4.  Effect of antiestrogen therapy on human mammary carcinomas with different estrogen receptor contents.

Authors:  H Westerberg; B Nordenskjold; O Wrange; J A Gustafsson; S Humla; N O Theve; C Silfverswärd; P O Granberg
Journal:  Eur J Cancer       Date:  1978-06       Impact factor: 9.162

5.  Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations.

Authors:  J M Nesland; R Holm; J V Johannessen; V E Gould
Journal:  J Pathol       Date:  1986-01       Impact factor: 7.996

6.  Cytochemical changes in the nucleus during tumour development.

Authors:  T Caspersson; G Auer; A Fallenius; J Kudynowski
Journal:  Histochem J       Date:  1983-04

7.  "Carcinoid" tumor of the breast. A variant of conventional breast cancer?

Authors:  J B Taxy; A S Tischler; S J Insalaco; H Battifora
Journal:  Hum Pathol       Date:  1981-02       Impact factor: 3.466

8.  Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers.

Authors:  J Arklie; J Taylor-Papadimitrious; W Bodmer; M Egan; R Millis
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

9.  Endocrine markers in argyrophilic carcinomas of the breast.

Authors:  G Bussolati; M Papotti; A Sapino; P Gugliotta; B Ghiringhello; J G Azzopardi
Journal:  Am J Surg Pathol       Date:  1987-04       Impact factor: 6.394

10.  Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.

Authors:  M M Roberts; R D Rubens; R J King; R A Hawkins; R R Millis; J L Hayward; A P Forrest
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  2 in total

1.  Management of neuroendocrine carcinomas of the breast: A rare entity.

Authors:  Yesim Yildirim; Sahende Elagoz; Ayhan Koyuncu; Cengiz Aydin; Kursat Karadayi
Journal:  Oncol Lett       Date:  2011-05-23       Impact factor: 2.967

2.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.

Authors:  N Durany; J Joseph; O M Jimenez; F Climent; P L Fernández; F Rivera; J Carreras
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.